A host of leading generics firms have banded together to call for an order to prevent leaks and potentially harmful public allegations, as they confront ongoing multi-district litigation over generics pricing in the US.
In a filing that reads like a Who’s Who of top generics firms, more than a dozen companies have asked a Pennsylvania district court to intervene with an order to stop parties to a multi-state lawsuit over generics pricing from leaking information and releasing prejudicial information to the press.
Apotex, Aurobindo, Citron, Dr Reddy’s and Glenmark are among the companies filing the request, along with Lannett, Lupin, Mayne Pharma, Mylan and Endo’s Par
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.
